Medication info

Kvarban Tablets 5/80 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tabletValsartan›80mg / 1 tablet
Manufacturer / importer
Farmgen Science Co., Ltd.
Appearance
Yellow round film-coated tablets
Packaging
30 tablets/box [(10 tablets/PTP x 3)]
Approval status
Expired

MFDS item code 202004050 · Approved 2020.05.29

This product's status changed to Expired on 2025.05.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension and heart failure; improvement of dyslipidemia; prevention of atherosclerosis, cardiovascular risk, and mortality
Who takes it
Adults · Children
Adult dose
This drug should be administered only to adults. The dosage should be individualized for each patient based on the efficacy and tolerability of each component, valsartan/rosuvastatin. ◆ Valsartan 1. Essential hypertension Take with water during or between meals. If possible, it is recommended to take the drug at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be administered concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Initiate treatment with this drug at 40 mg once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with this drug at 40 mg once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this drug. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with this drug at 40 mg once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with this drug at 40 mg once daily; the dose should not exceed 80 mg once daily. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this drug orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this drug, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction in the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended initial dose is 20 mg of this drug twice daily. Thereafter, over several weeks, the dose may be increased according to the patient's tolerability, using doses of 40 mg, 80 mg, and 160 mg per administration twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This drug may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dosage adjustment is necessary for creatinine clearance of 10 mL/min or higher. However, do not administer this drug to patients with creatinine clearance below 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this drug should preferably not exceed 80 mg. If doses of 80 mg or more per day are administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 mg once daily. 2. Older adults: No dosage adjustment is necessary. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this drug to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 5. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this drug is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this drug (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Farmgen Science Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure; improvement of dyslipidemia; prevention of atherosclerosis, cardiovascular risk, and mortality

  • Essential hypertension
  • heart failure
  • heart failure
  • left ventricular failure
  • left ventricular systolic dysfunction
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
View approved original text

This medication is used for patients who need to take both Valsartan and Rosuvastatin. Firstly, Valsartan is used for the treatment of essential hypertension and heart failure, especially in patients who are intolerant to ACE inhibitors. It also helps reduce the risk of death in stable patients with left ventricular dysfunction following a myocardial infarction. Rosuvastatin is primarily used as an adjunct when diet alone is insufficient in patients with hypercholesterolemia and mixed dyslipidemia. This medication is also used to slow the progression of atherosclerosis and to reduce the risk of stroke, myocardial infarction, and vascular revascularization in patients at high cardiovascular risk. Thus, this medication effectively improves hypertension, heart failure, hyperlipidemia, and the risk of cardiovascular diseases.

How to take

Adult dose

This drug should be administered only to adults. The dosage should be individualized for each patient based on the efficacy and tolerability of each component, valsartan/rosuvastatin. ◆ Valsartan 1. Essential hypertension Take with water during or between meals. If possible, it is recommended to take the drug at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be administered concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Initiate treatment with this drug at 40 mg once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with this drug at 40 mg once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this drug. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with this drug at 40 mg once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with this drug at 40 mg once daily; the dose should not exceed 80 mg once daily. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this drug orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this drug, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction in the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended initial dose is 20 mg of this drug twice daily. Thereafter, over several weeks, the dose may be increased according to the patient's tolerability, using doses of 40 mg, 80 mg, and 160 mg per administration twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This drug may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dosage adjustment is necessary for creatinine clearance of 10 mL/min or higher. However, do not administer this drug to patients with creatinine clearance below 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this drug should preferably not exceed 80 mg. If doses of 80 mg or more per day are administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 mg once daily. 2. Older adults: No dosage adjustment is necessary. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this drug to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 5. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this drug is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this drug (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication may cause severe harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Women of childbearing potential or nursing mothers should not take this medication and should use appropriate contraceptive methods. It is not safe for patients with severely impaired liver or kidney function, muscle diseases, or certain liver diseases to take this medication. Elderly patients or those with high serum potassium levels or impaired liver function should use this medication with particular caution, and regular blood tests and physical condition checks are necessary. This medication may cause muscle pain, muscle weakness, and, rarely, severe muscle damage (rhabdomyolysis), so any unusual symptoms in the muscles should be reported to the medical staff immediately. Furthermore, side effects such as liver dysfunction, allergic reactions, low blood pressure, and hyperkalemia may occur, so immediate consultation with a doctor is advisable if symptoms appear. This medication may interact with other medications, so if you are currently taking any other medicines, be sure to inform your doctor or pharmacist. In case of overdose, severe hypotension or altered consciousness may occur, so you must adhere strictly to the dosage and visit a medical institution immediately if an overdose occurs. Store in a place out of reach of children and do not transfer to another container.

Side effects

Dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, weakness, chest pain, facial swelling, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased blood levels of liver amino transferases (AST, ALT), increased blood creatine phosphokinase, increased blood potassium, increased gamma-glutamyl transferase, musculoskeletal stiffness, limb pain, sensory reduction, anxiety, upper respiratory infection, pharyngitis, tonsillitis, spinal stenosis, aphasia, oral hemorrhage, vomiting, insulin-dependent diabetes mellitus, diabetic complications, leg fracture, spinal fracture, fracture, skin mass, second-degree atrioventricular block, vestibulitis, retinal detachment, unspecified skin tumor-like conditions, herpes zoster, herniated disc, hemoptysis, sputum disease, bronchitis, dysesthesia, hoarseness, gastroesophageal reflux, diverticulitis, gastritis, stomatitis, carpal tunnel syndrome, chills, facial flushing, increased blood sugar, increased triglycerides, elevated blood pressure, worsening hypertension, neck/shoulder pain, toe fracture, osteomyelitis, skin infection, unspecified dermatitis, localized skin reaction, palpitations, worsening angina, auditory disturbances, overactive bladder, increased serum creatinine, benign prostatic hyperplasia, laceration, anemia, tinnitus, anxiety, decreased motor function, confusion, rash, myalgia, headache, dizziness, constipation, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle tear, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscular weakness, ocular myasthenia, hypotension, decreased consciousness, circulatory collapse, shock, tachycardia, bradycardia, orthostatic dizziness, orthostatic hypotension, kidney function impairment, hyperkalemia, angioedema, syncope, vascular edema, erythema, pruritus, serum sickness, vasculitis, interstitial pneumonia, hypoglycemia, shock, rhabdomyolysis, agranulocytosis, leukopenia, thrombocytopenia, reduced erythrocyte volume, decreased hemoglobin, viral infection, upper respiratory infection, cough, diarrhea, fatigue, rhinitis, sinusitis, abdominal pain, abdominal cramps, arthralgia, drowsiness, atrial fibrillation, thirst, loss of appetite, lethargy, syncope due to hypotension, loss of consciousness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a special container that blocks light. Additionally, to maintain the effectiveness of the medication, it should be stored at room temperature, between 1°C and 30°C.

Appearance and packaging

Appearance

Yellow round film-coated tablets

Package unit

30 tablets/box [(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.